Related Experiment Videos

[Noliprel efficiency in patients with hypertension]

Likars'Ka Sprava
|November 15, 2006
PubMed

Insights

Combination therapy with Noliprel (Perindopril/Indapamide) effectively lowers blood pressure in essential hypertension patients. This study highlights its positive impact on cardiac remodeling and safety profile.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Monotherapy for essential hypertension often yields suboptimal results.
  • Combination antihypertensive therapy offers potential for synergism and reduced adverse effects.
  • Essential hypertension management requires effective and safe treatment strategies.

Purpose of the Study:

  • To evaluate the efficacy and safety of low-dose Noliprel (Perindopril/Indapamide) in treating essential hypertension.
  • To investigate the impact of Noliprel on echocardiographic parameters and cardiac hemodynamics.
  • To assess the influence on myocardial remodeling processes.

Main Methods:

  • A 3-month prospective study involving 30 treatment-naive essential hypertension patients.
  • Prescription of low-dose Noliprel (2.00 mg Perindopril/0.625 mg Indapamide).
  • Detailed echocardiographic assessment including left ventricular myocardium mass index and wall thickness.

Main Results:

  • Noliprel demonstrated significant antihypertensive activity, achieving target blood pressure in 83.3% of patients within one month.
  • An additional 16.7% of patients required a dosage increase to achieve target blood pressure after 3 months.
  • Positive trends in echocardiographic parameters and cardiac hemodynamics were observed during therapy.

Conclusions:

  • Low-dose Noliprel is a highly effective and safe antihypertensive medication.
  • Noliprel positively influences myocardial remodeling processes.
  • The combination therapy is metabolically neutral with no observed side effects.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...